{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:50:20Z","timestamp":1775170220699,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Renal Nutrition"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1053\/j.jrn.2011.10.008","type":"journal-article","created":{"date-parts":[[2011,12,24]],"date-time":"2011-12-24T18:59:46Z","timestamp":1324753186000},"page":"191-194","source":"Crossref","is-referenced-by-count":17,"title":["Hyperhomocysteinemia in Chronic Renal Failure: Alternative Therapeutic Strategies"],"prefix":"10.1053","volume":"22","author":[{"given":"Alessandra F.","family":"Perna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Immacolata","family":"Sepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Maria","family":"Pollastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natale G.","family":"De Santo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Ingrosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jrn.2011.10.008_bib1","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3949\/ccjm.77a.10036","article-title":"The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease?","volume":"77","author":"Abraham","year":"2010","journal-title":"Cleve Clin J Med"},{"key":"10.1053\/j.jrn.2011.10.008_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1525-139X.2009.00579.x","article-title":"Hyperhomocysteinemia in uremia\u2014a red flag in a disrupted circuit","volume":"22","author":"Perna","year":"2009","journal-title":"Semin Dial"},{"key":"10.1053\/j.jrn.2011.10.008_bib3","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(03)13372-7","article-title":"Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uremia","volume":"361","author":"Ingrosso","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.jrn.2011.10.008_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.semnephrol.2005.06.006","article-title":"Therapy of hyperhomocysteinemia in chronic kidney disease","volume":"26","author":"Massy","year":"2006","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.jrn.2011.10.008_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jama.298.10.1163","article-title":"Veterans Affairs site investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial","volume":"298","author":"Jamison","year":"2007","journal-title":"JAMA"},{"key":"10.1053\/j.jrn.2011.10.008_bib6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/CIRCULATIONAHA.109.904672","article-title":"B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial","volume":"121","author":"Heinz","year":"2010","journal-title":"Circulation"},{"key":"10.1053\/j.jrn.2011.10.008_bib7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2215\/CJN.05310610","article-title":"Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis","volume":"6","author":"Qin","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2011.10.008_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/ndt\/17.5.865","article-title":"Hyperhomocysteinaemia therapy in hemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12","volume":"17","author":"Ducloux","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.jrn.2011.10.008_bib9","doi-asserted-by":"crossref","first-page":"30111","DOI":"10.1074\/jbc.M104324200","article-title":"Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine","volume":"276","author":"Sengupta","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1053\/j.jrn.2011.10.008_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1046\/j.1523-1755.2002.00151.x","article-title":"Plasma aminothiol oxidation in chronic hemodialysis patients","volume":"61","author":"Himmelfarb","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2011.10.008_bib11","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1046\/j.1523-1755.63.s84.33.x","article-title":"Possible mechanisms of homocysteine toxicity","volume":"63","author":"Perna","year":"2003","journal-title":"Kidney Int"},{"key":"10.1053\/j.jrn.2011.10.008_bib12","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1002\/rcm.2154","article-title":"Characterization of cysteinylation of pharmaceutical grade human serum albumin by electrospray ionization mass spectrometry and low-energy collision-induced dissociation tandem mass spectrometry","volume":"19","author":"Kleinova","year":"2005","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1053\/j.jrn.2011.10.008_bib13","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.bbrc.2004.10.191","article-title":"Plasma albumin cysteinylation is regulated by cystathionine beta-synthase","volume":"325","author":"Bar-Or","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.jrn.2011.10.008_bib14","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1001\/jama.2010.490","article-title":"Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial","volume":"303","author":"House","year":"2010","journal-title":"JAMA"},{"key":"10.1053\/j.jrn.2011.10.008_bib15","unstructured":"Jacob J, Zahi R, Guarino P, Kaufman J. Potential adverse myocardial effects of B-vitamin therapy: lessons from the HOST trial. In: 8th International Congress on Homocysteine Metabolism. Lisboa, 19-22 June 2011:52."},{"key":"10.1053\/j.jrn.2011.10.008_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/phrs.1999.0519","article-title":"N-acetyl-cysteine reduces homocysteine plasma levels after single intravenous administration by increasing thiols urinary excretion","volume":"40","author":"Ventura","year":"1999","journal-title":"Pharmacol Res"},{"key":"10.1053\/j.jrn.2011.10.008_bib17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1161\/01.CIR.0000109492.65802.AD","article-title":"Acetylcysteine reduces plasma homocysteine concentration and improves pulse and endothelial function in patients with endstage renal failure","volume":"1009","author":"Scholze","year":"2004","journal-title":"Circulation"},{"key":"10.1053\/j.jrn.2011.10.008_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00044011-200626040-00003","article-title":"Intravenous N-acetylcysteine during hemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease","volume":"26","author":"Thaha","year":"2006","journal-title":"Clin Drug Invest"},{"key":"10.1053\/j.jrn.2011.10.008_bib19","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00228-004-0850-0","article-title":"Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients","volume":"60","author":"Soldini","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.jrn.2011.10.008_bib20","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2215\/CJN.00210110","article-title":"Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease","volume":"5","author":"Nolin","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.jrn.2011.10.008_bib21","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/01.CIR.0000050628.11305.30","article-title":"The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure","volume":"107","author":"Tepel","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.jrn.2011.10.008_bib22","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/ajkd.2003.50054","article-title":"The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomised, controlled study","volume":"41","author":"Friedman","year":"2003","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of Renal Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051227611001981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051227611001981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T14:20:24Z","timestamp":1543328424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051227611001981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1051227611001981"],"URL":"https:\/\/doi.org\/10.1053\/j.jrn.2011.10.008","relation":{},"ISSN":["1051-2276"],"issn-type":[{"value":"1051-2276","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}